1. Clinical Overview
Interferon alfa-2b is a recombinant, non-glycosylated protein belonging to the type I interferon family. It is a highly purified, single-chain polypeptide containing 165 amino acids, produced by recombinant DNA technology using genetically engineered Escherichia coli. It possesses potent immunomodulatory, antiproliferative, and antiviral properties. In the Indian context, it is a critical therapeutic agent for several viral and neoplastic conditions, though its use has evolved with the advent of newer targeted therapies.
| Onset | Duration | Bioavailability |
|---|---|---|
| Immunomodulatory and antiviral effects begin within hours of administration, but clinical response (e.g., reduction in viral load, tumor shrinkage) may take weeks to months. | Biological effects can persist for several days after a single dose due to its induction of secondary mediators and prolonged cellular effects. | Approximately 80-90% after subcutaneous (SC) or intramuscular (IM) injection. Negligible (<1%) after oral administration. |
2. Mechanism of Action
Interferon alfa-2b exerts its effects by binding to specific cell surface receptors (IFNAR1 and IFNAR2), leading to the activation of the JAK-STAT signaling pathway. This results in the transcription of interferon-stimulated genes (ISGs), which mediate its antiviral, antiproliferative, and immunomodulatory actions.
3. Indications & Uses
- Chronic Hepatitis B infection (with evidence of viral replication and liver inflammation)
- Chronic Hepatitis C infection (as monotherapy or in combination with ribavirin, though now largely superseded by DAAs)
- Hairy Cell Leukemia
- Follicular Lymphoma (as maintenance therapy)
- Malignant Melanoma (adjuvant therapy)
4. Dosage & Administration
Adult Dosage: Varies widely by indication. **Chronic Hepatitis B:** 5-10 Million IU SC/IM thrice weekly for 16-24 weeks. **Chronic Hepatitis C (monotherapy):** 3 Million IU SC/IM thrice weekly for 48-52 weeks. **Hairy Cell Leukemia:** 2 Million IU/m² SC/IM thrice weekly for up to 6 months. **Follicular Lymphoma:** 5 Million IU SC thrice weekly for up to 18 months as maintenance. **Malignant Melanoma:** 20 Million IU/m² IV for 5 days/week for 4 weeks induction, then 10 Million IU/m² SC thrice weekly for 48 weeks maintenance.
Administration: For SC/IM use only. Reconstitute the lyophilized powder with provided sterile water for injection. Gently swirl, do not shake vigorously. Use immediately after reconstitution. Rotate injection sites (thigh, abdomen, upper arm). Administer in the evening to mitigate flu-like symptoms. Pre-medication with acetaminophen/paracetamol is common.
5. Side Effects
Common side effects may include:
- Flu-like syndrome (fever, chills, headache, myalgia, fatigue - often diminishes with continued therapy)
- Injection site reactions (erythema, pain)
- Anorexia, nausea
- Alopecia (reversible)
- Mild bone marrow suppression (anemia, neutropenia, thrombocytopenia)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Theophylline | Interferon alfa-2b inhibits cytochrome P450 1A2, increasing theophylline levels and risk of toxicity. | Major |
| Zidovudine (AZT) | Increased risk of myelosuppression (neutropenia, anemia). | Major |
| Ribavirin | Additive hemolytic anemia risk. Used therapeutically in combination for HCV but requires close hematological monitoring. | Major |
| Other Myelosuppressive Agents (e.g., chemotherapeutics, clozapine) | Increased risk of severe bone marrow suppression. | Major |
| Live Attenuated Vaccines | Theoretical risk of enhanced vaccine replication and infection. Avoid vaccination during therapy. | Moderate |
| CNS Depressants (e.g., alprazolam, opioids) | Potential additive sedative and neuropsychiatric effects. | Moderate |
7. Patient Counselling
- DO administer the injection at the same time on treatment days, preferably in the evening.
- DO rotate injection sites to prevent local reactions.
- DO store the vials/pens in the refrigerator (2-8°C). Do not freeze.
- DO use reconstituted solution immediately.
- DO keep a symptom diary to track side effects.
- DONT skip scheduled blood tests and follow-up visits.
- DONT change the dose or stop treatment without consulting your doctor.
- DONT share needles, syringes, or pens.
8. Toxicology & Storage
Overdose: Exaggeration of known adverse effects: severe fatigue, profound myelosuppression (pancytopenia), high fever, severe neuropsychiatric symptoms (confusion, coma), hepatorenal failure, and cardiovascular collapse.
Storage: Store unopened vials/pens at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light. For pre-filled pens or multi-dose vials, note the post-first-use storage duration as per manufacturer (typically up to 4 weeks at 2-8°C). Keep out of reach of children. Do not use if solution is discolored or contains particles. Transport in a cool bag if necessary.